News

In comparing the mortality rates after a year between those with cancer who engaged in more moderate-to-vigorous physical activity and those who were largely inactive, researchers have found that the people in the physical activity group had a 60 percent lower risk of mortality.

A class of medications used to treat type 2 diabetes, called GLP1 receptor agonists, may also reduce the risk of colorectal cancer, a new study shows.

UiB research reveals that around 20 per cent of all cases of the most severe form of breast cancer may arise from the small group of normal tissue cells carrying an epimutation of a specific gene.

The vital treatment for cancers of the head and neck, breast, cervix, prostate, and even eyes can harm the cells that keep bones strong. But scientists have developed a new strategy to protect bones during cancer treatment.

Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer.

A new study shows that tumor-associated macrophages, which are white blood cells that are found in breast tumors, can both help and hinder the spread of cancer cells to other organs.

Secreted frizzled-related protein 2 – a protein that promotes tumor growth and angiogenesis – has been associated with poor outcomes in pancreatic cancer patients.

Designing small molecule drugs that target the androgen receptor is a major challenge, but the way it forms condensates could reveal a new way of targeting the receptor.

Around one-third of patients with acute myeloid leukemia (AML) have a mutation that affects the NPM1 gene. According to research, the altered protein produced by this mutation intervenes in autophagy and enables leukemia cells to speed up their growth.

A breakthrough in the understanding of the relationship between a naturally occurring enzyme and the liver cancer drug sorafenib could improve the effectiveness of the drug.